Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective study
Yuki Miura(Japanese Red Cross Hadano Hospital), Chikara Οhyama(Hirosaki University), Shingo Hatakeyama(Hirosaki University), Tomonori Habuchi(Akita University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Norihiko Tsuchiya(Yamagata University), Takafumi Yanagisawa(Jikei University School of Medicine), Shintaro Narita(Akita University), Shigeto Ishidoya(Sendai City Hospital), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Senji Hoshi, Toshikazu Tanaka, Takahiro Kimura(Jikei University School of Medicine), Noritaka Ishi(Hirosaki University), Shin Egawa, Kenichi Hata(Jikei University School of Medicine)
Cited by 6
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282